Monoclonal antibody treatment combo reduces hospitalization among high-risk patients with COVID-19
In an observational study, Mayo Clinic researchers report that the combination of casirivimab and imdevimab—two monoclonal antibody treatments under Food and Drug Administration emergency use authorization—keep high-risk ...
Aug 30, 2021
0
76